InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should
August 18, 2023
